KR102676056B1 - 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 - Google Patents

비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 Download PDF

Info

Publication number
KR102676056B1
KR102676056B1 KR1020187021547A KR20187021547A KR102676056B1 KR 102676056 B1 KR102676056 B1 KR 102676056B1 KR 1020187021547 A KR1020187021547 A KR 1020187021547A KR 20187021547 A KR20187021547 A KR 20187021547A KR 102676056 B1 KR102676056 B1 KR 102676056B1
Authority
KR
South Korea
Prior art keywords
fatty liver
liver disease
alcoholic fatty
pharmaceutical composition
hydroxyphenyladenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187021547A
Other languages
English (en)
Korean (ko)
Other versions
KR20180100152A (ko
Inventor
하이보 주
휘지에 시
Original Assignee
베이징 구쉔 라이프 헬스 테크놀로지 컴퍼니 리미티드
인스티튜드 오브 머테리아 메디카, 차이니스 아케데미 오브 메디컬 싸이언시스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 구쉔 라이프 헬스 테크놀로지 컴퍼니 리미티드, 인스티튜드 오브 머테리아 메디카, 차이니스 아케데미 오브 메디컬 싸이언시스 filed Critical 베이징 구쉔 라이프 헬스 테크놀로지 컴퍼니 리미티드
Publication of KR20180100152A publication Critical patent/KR20180100152A/ko
Application granted granted Critical
Publication of KR102676056B1 publication Critical patent/KR102676056B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020187021547A 2015-12-31 2016-12-28 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 Active KR102676056B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511034199 2015-12-31
CN201511034199.0 2015-12-31
PCT/CN2016/112623 WO2017114413A1 (zh) 2015-12-31 2016-12-28 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (2)

Publication Number Publication Date
KR20180100152A KR20180100152A (ko) 2018-09-07
KR102676056B1 true KR102676056B1 (ko) 2024-06-19

Family

ID=59224622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187021547A Active KR102676056B1 (ko) 2015-12-31 2016-12-28 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도

Country Status (11)

Country Link
US (1) US11058703B2 (enExample)
EP (1) EP3398604A4 (enExample)
JP (1) JP7382716B2 (enExample)
KR (1) KR102676056B1 (enExample)
CN (2) CN118178446A (enExample)
AU (1) AU2016383376B2 (enExample)
CA (1) CA3010097C (enExample)
HK (1) HK1255689A1 (enExample)
RU (1) RU2759916C2 (enExample)
WO (1) WO2017114413A1 (enExample)
ZA (1) ZA201805080B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
SG11202011698VA (en) 2018-06-05 2020-12-30 Flagship Pioneering Innovations V Inc Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用
CN117599076A (zh) * 2023-11-15 2024-02-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101380140B1 (ko) * 2008-10-06 2014-04-01 인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스 트리아세틸-3-히드록실페닐아데노신 및 혈지조절에 대한 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) * 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
WO2012143813A1 (en) * 2011-04-22 2012-10-26 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
AU2013204489A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101380140B1 (ko) * 2008-10-06 2014-04-01 인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스 트리아세틸-3-히드록실페닐아데노신 및 혈지조절에 대한 용도

Also Published As

Publication number Publication date
CN118178446A (zh) 2024-06-14
JP2019500379A (ja) 2019-01-10
ZA201805080B (en) 2019-10-30
EP3398604A1 (en) 2018-11-07
AU2016383376A1 (en) 2018-07-12
RU2018126158A3 (enExample) 2020-03-11
KR20180100152A (ko) 2018-09-07
RU2759916C2 (ru) 2021-11-18
EP3398604A4 (en) 2019-06-19
CA3010097C (en) 2023-08-22
CN106943420A (zh) 2017-07-14
RU2018126158A (ru) 2020-01-31
US11058703B2 (en) 2021-07-13
WO2017114413A1 (zh) 2017-07-06
AU2016383376B2 (en) 2022-07-28
US20190022120A1 (en) 2019-01-24
CA3010097A1 (en) 2017-07-06
JP7382716B2 (ja) 2023-11-17
HK1255689A1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
KR102676056B1 (ko) 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도
US10925854B2 (en) Methods and compositions for preventing or treating fatty liver, protecting liver function or ameliorating liver diseases caused by fatty liver or other associated disorders
CN108619490A (zh) 一种长效化突变的人源成纤维生长因子的新用途
CN117599036A (zh) 隐绿原酸在制备治疗和/或预防非酒精性脂肪肝产品中的用途
CN110946986B (zh) 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用
KR20150130352A (ko) 지방간 질환을 치료하는 방법
CN119157865B (zh) 桤木酮及其类似物在脂肪性肝病预防及治疗中的应用
US20210196737A1 (en) Use of trezastilbenoside in manufacture of product for treating and/or preventing non-alcoholic fatty liver disease
US20240408162A1 (en) Use of Extract from Morus alba L. in the Preparation of a Medicament for Preventing and/or Treating a Hepatobiliary Disease
KR100979459B1 (ko) 근육세포에서 포도당 흡수를 증가시키는 데이츄 추출물과이로부터 분리한 4ｈ-크로멘-4-온 유도체
CN109985072A (zh) 榆黄蘑提取物在制备治疗脂肪肝的药物、保健品、食品中的应用
CN115607546A (zh) Isarubrolone C、包含Isarubrolone C的药物组合物及应用
US20180193401A1 (en) Anti-obesity composition comprising natural complex
CN111000852B (zh) 苦蘵中睡茄内酯提取物在制备预防或治疗非酒精性脂肪性肝病的药物中应用
CN117100739B (zh) 负调节Nrf2信号通路的小分子组合物及其应用
KR100343923B1 (ko) 창이자 추출물을 이용한 백내장 예방 및 치료 조성물 및그 제조방법
CN114788825A (zh) Magl抑制剂的医药用途
CN103735549A (zh) 盐酸去亚甲基小檗碱在制备治疗非酒精性脂肪肝病药物中的应用
KR20070044198A (ko) 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN110613712A (zh) 中药组合物及其在治疗血管炎症和内皮损伤中的应用
CN120983451A (zh) 柯里拉京在制备预防或治疗代谢相关脂肪性肝病产品中的应用
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
CN106389455B (zh) 一种用于预防或治疗非酒精性脂肪肝的多甲氧基黄酮、组合物及其药物制剂
WO2023115294A1 (zh) 脑心通制剂在制备治疗非酒精性脂肪肝药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601